Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JN.2.5ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
JN.2.5ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
JN.2.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.16 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.16 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.16 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.16 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.46.1 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.46.1 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.46.1 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.46.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.37 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.37 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.37 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.37 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.336ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.336ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.336ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.336NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.1.9ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BA.5.1.9ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BA.5.1.9ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BA.5.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.317ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.1.317ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.1.317ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.1.317NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.397ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.1.397ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.1.397ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.1.397NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.6.1ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
CM.6.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.54ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BA.5.2.54ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BA.5.2.54ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BA.5.2.54NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DR.2ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
DR.2ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
DR.2ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
DR.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.27ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-13753.9France
BF.7.27ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BF.7.27ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BF.7.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.26ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.1.26ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.1.26ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.1.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.8ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used